Trial Outcomes & Findings for Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL) (NCT NCT00747227)

NCT ID: NCT00747227

Last Updated: 2011-11-11

Results Overview

Snellen Equivalent visual acuity of 20/40 or better

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

250 participants

Primary outcome timeframe

One year

Results posted on

2011-11-11

Participant Flow

250 subjects from normal cataract populations who were undergoing primary phacoemulsification with lens implantation and did not have any other visually significant ocular pathologies were selected at 12 investigation sites across the country

Participant milestones

Participant milestones
Measure
ZV9003 Intraocular Lens
modified light transmission intraocular lens
ZA9003 Intraocular Lens
monofocal acrylic intraocular lens
Overall Study
STARTED
126
124
Overall Study
COMPLETED
120
120
Overall Study
NOT COMPLETED
6
4

Reasons for withdrawal

Reasons for withdrawal
Measure
ZV9003 Intraocular Lens
modified light transmission intraocular lens
ZA9003 Intraocular Lens
monofocal acrylic intraocular lens
Overall Study
Death
3
1
Overall Study
Withdrawal by Subject
1
0
Overall Study
Lost to Follow-up
1
2
Overall Study
Illness
1
1

Baseline Characteristics

Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
ZV9003 Intraocular Lens
n=126 Participants
modified light transmission intraocular lens
ZA9003 Intraocular Lens
n=124 Participants
monofocal acrylic intraocular lens
Total
n=250 Participants
Total of all reporting groups
Age Continuous
73.3 years
STANDARD_DEVIATION 8.0 • n=5 Participants
71.5 years
STANDARD_DEVIATION 8.0 • n=7 Participants
72.4 years
STANDARD_DEVIATION 8.0 • n=5 Participants
Age, Customized
<60 years
4 participants
n=5 Participants
8 participants
n=7 Participants
12 participants
n=5 Participants
Age, Customized
Between 60 and 69 years
35 participants
n=5 Participants
41 participants
n=7 Participants
76 participants
n=5 Participants
Age, Customized
Between 70 and 79 years
57 participants
n=5 Participants
54 participants
n=7 Participants
111 participants
n=5 Participants
Age, Customized
>=80
30 participants
n=5 Participants
21 participants
n=7 Participants
51 participants
n=5 Participants
Sex: Female, Male
Female
78 Participants
n=5 Participants
68 Participants
n=7 Participants
146 Participants
n=5 Participants
Sex: Female, Male
Male
48 Participants
n=5 Participants
56 Participants
n=7 Participants
104 Participants
n=5 Participants
Region of Enrollment
United States
126 participants
n=5 Participants
124 participants
n=7 Participants
250 participants
n=5 Participants

PRIMARY outcome

Timeframe: One year

Population: One subject was excluded from the analysis because the ZV9003 lens was implanted in the first eye and the ZA900 lens was implanted in the second eye. All subjects in the outcomes analysis had the same lens in both eyes.

Snellen Equivalent visual acuity of 20/40 or better

Outcome measures

Outcome measures
Measure
ZV9003 Intraocular Lens
n=119 Participants
modified light transmission intraocular lens
ZA9003 Intraocular Lens
n=120 Participants
monofocal acrylic intraocular lens
Best Corrected Distance Visual Acuity
119 participants
120 participants

PRIMARY outcome

Timeframe: One Year

Population: One subject was excluded from the analysis because the ZV9003 lens was implanted in the first eye and the ZA900 lens was implanted in the second eye. All subjects in the outcomes analysis had the same lens in both eyes.

Snellen Equivalent of 20/40 or better at one year

Outcome measures

Outcome measures
Measure
ZV9003 Intraocular Lens
n=119 Participants
modified light transmission intraocular lens
ZA9003 Intraocular Lens
n=120 Participants
monofocal acrylic intraocular lens
Uncorrected Distance Visual Acuity
110 participants
116 participants

SECONDARY outcome

Timeframe: 4-6 months

Population: Binocular contrast sensitivity testing was reported for all binocular subjects with data available at the 4-6 month visit on 120 subjects in each group. One ZA9003 subject was tested at 3.0 cpd and not tested for 6.0 cpd through 18.0 cpd (mesopic and photopic). Testing for levels 6.0 through 18.0 were not reported.

Contrast sensitivity is the measurement of how faded an image may become before it can clearly be seen. Contrast sensitivity was measured in photopic and mesopic conditions at the following spatial frequencies: 3.0, 6.0, 12.0, and 18 cpd (cycles per degree). Contrast sensitivity is measured in log units. A higher value for the logarithmic units translates to better contrast sensitivity.

Outcome measures

Outcome measures
Measure
ZV9003 Intraocular Lens
n=120 Participants
modified light transmission intraocular lens
ZA9003 Intraocular Lens
n=120 Participants
monofocal acrylic intraocular lens
Contrast Sensitivity
Mesopic condition at 3.0 cpd
1.62 log contrast
Interval 1.58 to 1.66
1.62 log contrast
Interval 1.58 to 1.66
Contrast Sensitivity
Mesopic condition at 6.0 cpd
1.65 log contrast
Interval 1.61 to 1.69
1.63 log contrast
Interval 1.58 to 1.68
Contrast Sensitivity
Mesopic condition at 12.0 cpd
1.14 log contrast
Interval 1.07 to 1.21
1.17 log contrast
Interval 1.1 to 1.24
Contrast Sensitivity
Mesopic condition at 18.0 cpd
0.60 log contrast
Interval 0.54 to 0.66
0.65 log contrast
Interval 0.59 to 0.71
Contrast Sensitivity
Photopic condition at 3.0 cpd
1.76 log contrast
Interval 1.73 to 1.79
1.74 log contrast
Interval 1.71 to 1.78
Contrast Sensitivity
Photopic condition at 6.0 cpd
1.91 log contrast
Interval 1.88 to 1.94
1.94 log contrast
Interval 1.91 to 1.98
Contrast Sensitivity
Photopic condition at 12.0 cpd
1.58 log contrast
Interval 1.54 to 1.62
1.59 log contrast
Interval 1.55 to 1.64
Contrast Sensitivity
Photopic condition at 18.0 cpd
1.09 log contrast
Interval 1.04 to 1.14
1.14 log contrast
Interval 1.09 to 1.19

SECONDARY outcome

Timeframe: One Year

Population: Two subjects in the ZV9003 group did not complete the one year questionnaire.

Subjects indicating a subjective response to a multiple choice question, "At the present time, would you say your eyesight using both eyes (with glasses or contact lenses, if you wear them) is excellent, good, fair, poor, or very poor or are you completely blind?", on a multi-item questionnaire administered by interviewer to determine subject satisfaction with their overall visual outcome at the one year visit.

Outcome measures

Outcome measures
Measure
ZV9003 Intraocular Lens
n=118 Participants
modified light transmission intraocular lens
ZA9003 Intraocular Lens
n=119 Participants
monofocal acrylic intraocular lens
Subject Satisfaction - Subjects Satisfied With Overall Eyesight Rated as "Good" or "Excellent".
112 participants
113 participants

Adverse Events

ZV9003 Intraocular Lens

Serious events: 1 serious events
Other events: 0 other events
Deaths: 0 deaths

ZA9003 Intraocular Lens

Serious events: 1 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
ZV9003 Intraocular Lens
n=126 participants at risk
modified light transmission intraocular lens
ZA9003 Intraocular Lens
n=124 participants at risk
monofocal acrylic intraocular lens
Eye disorders
Retinal Tear requiring secondary surgical intervention
0.79%
1/126 • Number of events 1
0.81%
1/124 • Number of events 1

Other adverse events

Adverse event data not reported

Additional Information

Nicholas Taranatino, O.D., Head, Global Clinical Research & Devlopment

Abbott medical Optics, Inc.

Phone: 866-427-8477

Results disclosure agreements

  • Principal investigator is a sponsor employee PIs may not publish or disclose study data without Sponsor's prior written approval.
  • Publication restrictions are in place

Restriction type: OTHER